In collaboration with an international team, researchers at Karolinska Institutet in Sweden have developed an antibody, 3F7, which blocks a protein that is active in
the coagulation system factor XII.
These cells, in turn, instruct
factor - VIII — specific immune cells to become tolerant to the
coagulation protein, resulting in suppression of misdirected antibody responses to the replacement therapy — all without affecting the rest of the immune
system.